Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 1;10(1):22.
doi: 10.1186/s40794-024-00231-2.

The role of antibody-dependent enhancement in dengue vaccination

D G Aynekulu Mersha  1 , I van der Sterren  2 , L P M van Leeuwen  2 , T Langerak  2 , M S Hakim  3 , B Martina  4 , S F L van Lelyveld  5 , E C M van Gorp  2
Affiliations

The role of antibody-dependent enhancement in dengue vaccination

D G Aynekulu Mersha et al. Trop Dis Travel Med Vaccines. .

Abstract

Dengue is the most rapidly spreading vector-borne disease worldwide, with over half the global population at risk for an infection. Antibody-dependent enhancement (ADE) is associated with increased disease severity and may also be attributable to the deterioration of disease in vaccinated people. Two dengue vaccines are approved momentarily, with more in development. The increasing use of vaccines against dengue, combined with the development of more, makes a thorough understanding of the processes behind ADE more important than ever. Above that, due to the lack of treatment options, this method of prevention is of great importance. This review aims to explore the impact of ADE in dengue vaccinations, with the goal of enhancing potential vaccination strategies in the fight against dengue.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Organizational chart showing the different mechanisms of antibody-dependent enhancement
Fig. 2
Fig. 2
Schematic representation of Antibody-dependent enhancement in dengue infections. Antibody-dependent enhancement in dengue infections has both an extrinsic and an intrinsic component
Fig. 3
Fig. 3
Schematic representation of the dengue virus (A), the tetravalent vaccines Dengvaxia (B) and Qdenga (C) and the vaccine formulation TV003/TV005 (D). The dengue virus has an RNA genome with an open reading frame surrounded by untranslated regions. The open reading frame contains the genetic coding for three structural and seven non-structural (NS) proteins. The three structural proteins (capsid (C), premembrane (prM), and envelope)) form the structural components of the dengue virus particle
See this image and copyright information in PMC

References

    1. Scientific Working Group on Dengue. Meeting (2006: Geneva S, diseases UWBWSPfRaTiT. Report of the Scientific Working Group meeting on Dengue, Geneva, 1–5 October 2006. Report on dengue. Geneva: World Health Organization; 2007.
    1. Messina JP, Brady OJ, Golding N, Kraemer MUG, Wint GRW, Ray SE, et al. The current and future global distribution and population at risk of dengue. Nat Microbiol. 2019;4(9):1508–15. - PMC - PubMed
    1. Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929–32. - PMC - PubMed
    1. Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and long-term safety of a Dengue Vaccine in regions of Endemic Disease. N Engl J Med. 2015;373(13):1195–206. - PubMed
    1. Ooi EE, Kalimuddin S. Insights into dengue immunity from vaccine trials. Sci Transl Med. 2023;15(704):eadh3067. - PubMed

LinkOut - more resources